MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.

Amgen (NASDAQ:AMGN) stock in focus as company starts Phase 3 trials for obesity drug MariTide, aiming to challenge Eli Lilly ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.

Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...

Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections. But MariTide, which is Amgen's GLP-1 drug, only needs to be ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...